Dr. Nauman Chaudhry, MD
Dr. Nauman Chaudhry, MD is the managing partner of Retina Group of New England. Dr. Chaudhry is a nationally recognized vitreo-retinal surgeon who received the Honor Award by the American Society of Retina Specialists (ASRS) for his academic and research contributions. He is also an active member of the prestigious, invitation-only Retina Society and Macula Society. Dr. Chaudhry is the first principal investigator in Connecticut for two Gene Therapy clinical trials for age-related macular degeneration.
Dr. Chaudhry attended medical school at the Aga Khan University in Karachi, Pakistan and graduated with the highest honors in ophthalmology. He then completed his residency at the Yale Eye Center in New Haven where he served as chief resident. He was awarded the Marvin Sears Award for Excellence in Clinical Ophthalmology, given to Yale’s best ophthalmology residents. Dr. Chaudhry completed a second chief residency at the Bascom Palmer Eye Institute at the University of Miami, where he also finished his medical and surgical retina fellowship. Bascom Palmer has been consistently named the best eye hospital in the United States by U.S. News & World Report.
Dr. Chaudhry also had the distinguished honor of being in the top one percentile for both parts of the United States Medical Licensing Exam (USMLE).
Dr. Chaudhry is currently an Assistant Clinical Professor of Ophthalmology at the Yale School of Medicine. He is board-certified in Ophthalmology and serves as an examiner for the American Board of Ophthalmology. He is also a scientific reviewer for the prestigious American Journal of Ophthalmology, Retina, Ophthalmology Retina, Journal of Vitreoretinal Diseases and American Journal of Case Reports. Dr. Chaudhry recently received the Distinguished Contributor Award for outstanding contributions to the Journal of Vitreoretinal Diseases.
Dr. Chaudhry has authored more than 120 papers and abstracts in peer-reviewed ophthalmology literature. His research has included topics in retinal detachment, diabetic retinopathy, age-related macular degeneration, macular holes, ocular trauma, endophthalmitis and ocular complications. He was the principal investigator of clinical trials for the treatment of age-related macular degeneration, retinal vein occlusions and diabetic macular edema which led to the FDA approval of Lucentis, Eylea, Iluvien, Beovu, Vabysmo, Syfovre, lzervay and Eyelea HD. These drugs are now the standard of care for treatment of those potentially blinding eye conditions. Dr. Chaudhry oversees the biggest clinical research center for retinal and macular diseases in Connecticut and is currently the principal investigator in several pioneering national clinical trials for the treatment of Dry AMD, Exudative AMD, Diabetic Retinopathy and Retinal Vein Occlusion.
Dr. Chaudhry is accepting new patients in our Waterford, Norwich and Guilford offices.